BOUND THERAPEUTICS LLC

Marlton, NJ · Biotech · Private

miR-blocking therapeutic agent using bridged nucleic acid (BNA) conjugated to an IGF-1R-targeting peptide ligand for triple-negative breast cancer

nikitarna.com →
Grants
$600K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
6
1 granted · 5 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · microRNA-21 Blockade of Triple Negative Breast Cancer$299,774
Federal grantDepartment of Health and Human Services · Phase I · microRNA-21 Blockade of Triple Negative Breast Cancer$299,774
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1367NANO BIOTHERAPEUTICS INC——
1368ARTUS THERAPEUTICS INC.——
1369Curebiotech, Inc.——
1370BOUND THERAPEUTICS LLC——
1371BioHybrid Solutions LLC——
1372VERACHEM LLC——
1373SARFEZ PHARMACEUTICALS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 6
  • Compositions and Methods for MYC Messenger RNA Inhibitorsapplication
  • Compositions and Methods for MYC Messenger RNA Inhibitorsgranted
  • Compositions And Methods For The Treatment Of Cancerapplication
  • Compositions And Methods For Myc Messenger Rna Inhibitorsapplication
  • Compositions and Methods for MYC Messenger RNA Inhibitorsapplication
  • Compositions And Methods For The Treatment Of Cancerapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.